Erinn Maury knew Remicade wasn’t the right drug for Patti Schulte, a rheumatoid arthritis patient the physician saw at her Millersville, Maryland, practice. Schulte’s swollen, painful joints hadn’t responded to Enbrel or Humira, two drugs in the same class.
Pfizer and Arvinas plan vepdegestrant programme expansion after data at SABCS – Pharmaceutical Technology
Share this article Vebdegestrant is a proteolysis targeting chimera (PROTAC) being investigated by Pfizer and Arvinas for the treatment of breast cancer. Credit: Guillermo Spelucin